複雑性尿路感染症に対するCefmenoxime (CMX)の臨床的検討

Abstract

1回2 g, 1日2回の点滴静注を5日間連用し, 解析対象となし得た29例についての総合臨床効果は, 著効1, 有効15, 無効13例であった.そのうち, カテーテル留置例14例の有効率50%, 非留置例15例の有効率は60%であった.菌消失率は35株中27株(77.1%)であった.副作用としては1例に軽度下痢を認めたほか臨床検査で血清トランスアミナーゼの上昇4例, 血清クレアチニンの上昇2例を認めた

Cefmenoxime (CMX), a new semisynthetic antibiotic, was administrated in 29 cases diagnosed as complicated urinary tract infection. All patients received drip injection of 2 g (twice a day) for 5 days. Clinical results were excellent in 1 patient (3.4%), good in 15 patients (51.8%) and poor in 13 patients (44.8%). Effectiveness rate was 55.2%. In bacteriological response, out of 35 strains 27 (77.1%) strains were eradicated and 8 (22.9%) strains persisted. As for side effects, except one case of transient diarrhea after administration, no noteworthy reactions were observed. Laboratory abnormalities attributed to CMX treatment consisted of 4 cases of elevated serum transaminase and 2 cases of elevated serum creatinine.